

Please amend the application as follows:

In the Claims

Please cancel Claim 17. Please amend Claims 1-4, 8-11, 13-16, 19-23 and 26-28 as follows:

1. (Amended) A [retroviral vector carrying] method for producing a recombinant retroviral particle, said particle comprising a DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, [or an antisense SDI-1 DNA sequence] comprising stably transfecting a producer cell with a retroviral vector comprising the DNA sequence, said producer cell additionally harboring at least one DNA construct coding for proteins required for said retroviral vector to be packaged.
2. (Amended) [A] The method of Claim 1 wherein the retroviral vector [according to Claim 1 carrying] carries a DNA sequence encoding SDI-1.
3. (Amended) [A retroviral vector according to] The method of Claim [1] 2 wherein the DNA sequence codes for amino acids 1 to 71 of human SDI-1.
4. (Amended) [A retroviral vector according to] The method of Claim [1] 2 wherein the DNA sequence codes for amino acids 42 to 58 of human SDI-1.
8. (Amended) [A retroviral vector according to] The method of Claim 1, wherein the retroviral vector comprises a 5' LTR region of the structure U3-R-U5; one or more sequences selected from coding and noncoding sequences; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence containing a regulatory element or a promoter, followed by the U5 and R region, characterized in that at least one of the coding sequences is a DNA sequence encoding SDI-1, a functional analogue thereof, or a fragment thereof, [or an antisense SDI-1 DNA] said sequence [which is] being under transcriptional control of said regulatory element or promoter.

9. (Amended) [A retroviral vector according to] The method of Claim 1 wherein the DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, [or the antisense SDI-1 DNA sequence] is under transcriptional control of a target cell specific regulatory element or a target cell specific promoter or an X-ray inducible promoter.
10. (Amended) [A retroviral vector according to] The method of Claim 9 wherein the target cell specific regulatory element is [the] selected from the WAP and MMTV regulatory elements.
11. (Amended) [A retroviral vector according to] The method of Claim 10 [which] wherein the retroviral vector is pLXS-SDI1.
- 5113  
13. (Amended) A [packaging] producer cell [line harbouring:  
a) a retroviral vector according to Claim 1; and  
b)] stably transfected with a retroviral vector comprising a DNA sequence encoding SDI-1, a functional analogue thereof, or a fragment thereof, said producer cell additionally harboring at least one DNA construct coding for the proteins required for said retroviral vector to be packaged.
14. (Amended) [A packaging] The producer cell [line according to] of Claim 13 which is of human origin.
15. (Amended) [Encapsulated cells comprising a core containing packaging cells according to] A capsule which encapsulates the producer cell of Claim 13 [and a porous capsule wall surrounding said core], said capsule comprising a porous capsule wall being permeable to the retroviral particles produced by said [packaging cells] producer cell.
16. (Amended) [Encapsulated cells according to] The capsule of Claim 15 wherein said porous capsule wall [consists of] comprises a polyelectrolyte complex formed from counter charged polyelectrolytes.

19. (Amended) A pharmaceutical composition comprising [a recombinant retroviral particle according to Claim 17] the producer cell of Claim 13 and a pharmaceutically acceptable carrier or diluent.
20. (Amended) A pharmaceutical composition comprising [a packaging cell line according to] the capsule of Claim [13] 15 and a pharmaceutically acceptable carrier or diluent.
21. (Amended) [The use or a retroviral particle according to Claim 17 for the preparation of a medicament for the treatment of] A method of treating disorders or diseases responsive to the anti-proliferative activity of SDI-1 in an individual, comprising administering to the individual the capsule of Claim 15.
22. (Amended) The [use] method according to Claim 21 [for the preparation of a medicament for the treatment of] wherein the disorder or disease is [a] cancer[.] or restenosis.
23. (Amended) The [use] method according to Claim 22 [for the preparation of a medicament for the treatment of] wherein the cancer is breast cancer.
26. (Amended) A method for introducing DNA sequences encoding SDI-1, a functional analogue, or a fragment thereof, [or an antisense SDI-1 DNA sequence] into human cells in vitro or in vivo comprising infecting a target cell population with a retroviral particle [according to] produced by the producer cell line of Claim [17] 13.
27. (Amended) A method for the treatment of a disorder or disease responsive to the [antiproliferative] antiproliferative activity of SDI-1 comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a retroviral particle [according to] produced by the producer cell line of Claim [17] 13.
28. (Amended) A method according to Claim 27 wherein the disorder or disease is a cancer[.] or restenosis.